Sara Tolaney
@stolaney1
Followers
12K
Following
25K
Media
421
Statuses
6K
Chief, Division of Breast Oncology @DanaFarber Tennis fan Mother of two teenage girls
Boston. MA
Joined December 2015
Join Dr. Chao Cao (@ChaoCCao) as he presents in the Poster Spotlight Session 8 on "Weight Trajectories in the #BreastCancer Weight Loss (#BWEL) Trial" during the #SABCS25 session on weight and #GLP1 therapies. 🗓️ Thurs Dec. 11 ⏰ 7:00 - 8:30 am CST (8:00 - 9:30 am EST) 📍 221
0
2
3
Dr. Guilherme Nader-Marta (@GuiNaderMarta) will be presenting at tomorrow's #SABCS25 Poster Spotlight 9 on the Genomic, Transcriptomic, and Immune Hallmarks of Metastatic #LobularBreastCancer. 🗓️ Thurs, Dec. 11 ⏰ 7:00 - 8:30 am CST (8:00 - 9:30 am EST) 📍 Hemisfair 1-2
0
2
6
#SABCS2025 Aditya Bardia presents lidERA results - the first new ET in HR+ ESBC in a very long time to change IDFS. impressive data in high risk ESBC, less so in medium risk but very early. 84% AI, 16% tam on control. 70% hi risk. @OncoAlert
0
6
13
Nationwide Push-to-Talk Radios. Keep Your Family Safe Anywhere. Instant Communication for Work & Home
0
29
242
A panel of physicians and an AI model presented by Mohammad Jahanzeb each evaluated a patient case and recommended a treatment plan, and panelists compared the results during a special #SABCS25 Clinical Case Discussion moderated by Harold Burstein. @OncDocMJ @DrHBurstein
1
5
11
Primary analysis of the randomized phase III trial HER2CLIMB-02: Tucatinib and trastuzumab emtansine for patients with previously treated HER2-positive locally advanced and #MetastaticBreastCancer 🔓 https://t.co/UyLjdG99Lq
@LoiSher @stolaney1 @ErikaHamilton9 @curijoey @awolff
0
2
3
You may not know it's there, but Fusarium ear rot can hit your yield & crop quality hard. 🌽 Hear tips from Tyler Harp on how to protect your corn with Miravis Neo.
1
5
21
Positive Lidera results including ddfs. Exciting results. Unanswered question is where to place it with cdk46i. But obviously favorable tox profile. Would consider it a soc option when approved. @dradityabardia @SABCSSanAntonio #SABCS2025 #bcsm
0
4
8
OS data shown below. TDXd clearly a winner over TROP2 ADCs in first line for HR+|HER2 low but OS data and possible immune effect intriguing. Longer FU needed. Interestingly clearly better in TNBC. Huge heterogeneity in chemo sensitivity cannot be assessed.
#SABCS2025 Komal Jhaveri presents our data from Ascent 07. No difference in PFS first line chemo for HR+ MBC post ET by BICR but high censoring as inv changed therapy due to new lesions not called by BICR. Trend in OS interesting. Role in HER20 remains. @OncoAlert
1
8
14
Lidera is a big step forward with a new endocrine agent in early-stage ER+ breast cancer Lots of questions to address, but so important for patients!!! @OncoAlert #SABCS25
0
6
15
Being gay takes fortitude and true grit, and in order to have these superpowers, you have to embrace the marvel that you are. GAY LIKE ME is a celebration of gay identity, and a powerful warning for gay men and the world.
2K
6K
27K
lidERA: Giredestrant vs SOC ET as adj tx (85% AI) for ER+ BC Median f/u 32 mo Eligibility: pN0, T>1cm, g3, or Ki67≥20% or high genomic assay, or T4N0 OR Node + n=4170, 21% N0, 47% N1, 31% N2-3 iDFS: 92.4% vs 89.6% HR 0.70 p=0.0014 Stage 1 HR 0.89 DRFI 0.69 Interim OS 0.79
2
3
14
DATO-Base: 30% intracranial response rate with Dato-DXd among patients with LMD. Median OS exceeding 1 year among patients without prior ADC receipt. Join us at the #SABCS25 poster today to review the results in depth!
At today’s #SABCS25 @DanaFarber’s @PTarantinoMD presents new findings from the DATO-Base study examining treatment w/theADC Dato-DXd for women with leptomeningeal disease. BC is the most common cancer linked to this rare but serious condition
0
4
10
ASCENT-07: sacituzumab govitecan vs TPC as 1L chemo in HR+ MBC by @jhaveri_komal median f/u 15.4 mo n=690 TPC (43% cape, 57% taxane) PFS by BICR 8.3 mo vs 8.3 mo, HR 0.85,p=.13 Inv PFS 8.4 vs 6.4 (HR 0.78) OS HR 0.72 (61% in TPC recv'd subsequent ADC) @OncoAlert #SABCS25
0
7
15
Ciara O’Sullivan gives an excellent discussion of these results. Here I include the comparative patina results in HR+/HER2+ where all had ET. This is very important - why are docs not using ET in this setting? It works!!
#SABCS25 @ErikaHamilton9 presents HER2Climb05. Tucatinib prolonged PFS added to HP maintenance for HER2+ MBC. <50% of HR+ got ET! Why?? More toxicity but manageable. PFS in both arms shorter than Patina similar HRatio. Effect bigger in HR negative, maybe best there? @OncoAlert
2
4
14
Know what your customers love, want, and need from your business in 15 minutes a week.
0
0
0
@IlanaSchlam beautifully presenting 6 month follow up from TRADE adjuvant abemaciclib study, confirming benefit of early dose escalation improving drug tolerability. @DFCI_BreastOnc #SABCS25
0
7
23
Researchers are finding ways to turn cancer's weaknesses into treatment opportunities. Komen grantee @npriedig shared a new approach that uses a tumor's own abnormal RNAs to help find and attack cancer cells at #SABCS25. @SABCSSanAntonio
0
3
9
San Antonio Breast Cancer Symposium Co-Directors Carlos Arteaga, MD, and Virginia Kaklamani, MD, share their greetings for attendees in a new SABCS Meeting News article. Read now: https://t.co/oTE9Y0akUS
0
3
11
Dr. Nolan Priedigkeit presents data showing dramatic genomic evolution in ER+ MBC early vs late in disease course. -Frequent alterations in DNA repair, cell cycle, endocrine, and growth factor genes -Structural variation is a dominant mechanism of evolution
1
7
18
Take the Ferry to NYC. Kids Ride Free Thru Jan 4. All Terminals & Routes. Free Shuttles to Attractions. Watch Video. Click for Routes & Schedules.
0
4
24
Excellent presentation by @matteolambe showing AI improved DFS and TTDR over SERMs in HR+/HER2+ early breast cancer—without OS differences—benefit must be weighed against the higher risk of side effects! #bcsm #SABCS25
0
6
8
CSF ctDNA can also uncover mutations that confer resistance to current treatment - and can identify a potential new treatment option. #SABCS25
0
0
2